靶向人βc受体抑制转基因小鼠接触性皮炎
该研究构建了造血细胞特异性表达人βc受体(替代小鼠βc)的转基因小鼠,用于在体内测试人βc抑制剂。在过敏性接触性皮炎(ACD)模型中,抗人βc抗体CSL311显著抑制耳廓增厚和典型组织病理改变,并减少中性粒细胞、肥大细胞和嗜酸性粒细胞浸润,提示GM-CSF和IL-5而非IL-3是ACD的主要介质。
要点
- 人βc受体转基因小鼠可支持人βc抑制剂在ACD模型中的体内测试。
- 抗人βc抗体CSL311抑制ACD耳廓增厚及组织病理改变。
- CSL311减少ACD皮肤中中性粒细胞、肥大细胞和嗜酸性粒细胞聚集。
核心结论
- GM-CSF和IL-5而非IL-3是过敏性接触性皮炎的主要介质。
- 人βc受体转基因小鼠是体内测试βc抑制剂的独特平台。
研究设计与样本
- 研究构建人βc受体转基因小鼠,造血细胞特异性表达人βc替代小鼠βc。
- 在ACD模型中比较转基因小鼠与野生型小鼠的组织病理和细胞炎症。
- 使用抗人βc抗体CSL311在ACD模型中评估体内抑制效果。
主要发现
- 人βc受体转基因细胞在体外对小鼠GM-CSF和IL-5有反应,对IL-3无反应。
- 转基因小鼠在ACD模型中发生与野生型小鼠相当的组织病理和细胞炎症。
- Il3-/-小鼠在ACD模型中发生与野生型小鼠相当的组织病理。
- CSL311强烈抑制ACD典型的耳廓增厚和组织病理改变。
- CSL311减少ACD皮肤中中性粒细胞、肥大细胞和嗜酸性粒细胞聚集。
临床怎么用
- 提示同时靶向GM-CSF和IL-5信号(经βc)可能抑制ACD炎症。
- 人βc受体转基因小鼠可用于临床前评估人βc靶向抑制剂。
局限性
- 研究基于转基因小鼠ACD模型,尚未在人体中验证。
- βc的种属特异性限制了直接在小鼠中测试人βc抑制剂,需依赖转基因模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allergic contact dermatitis (ACD) is a prevalent and poorly controlled inflammatory disease caused by skin infiltration of T cells and granulocytes. The beta common (βc) cytokines GM-CSF, IL-3, and IL-5 are powerful regulators of granulocyte function that signal through their common receptor subunit βc, a property that has made βc an attractive target to simultaneously inhibit these cytokines. However, the species specificity of βc has precluded testing of inhibitors of human βc in mouse models. To overcome this problem, we developed a human βc receptor transgenic mouse strain with a hematopoietic cell‒specific expression of human βc instead of mouse βc. Human βc receptor transgenic cells responded to mouse GM-CSF and IL-5 but not to IL-3 in vitro and developed tissue pathology and cellular inflammation comparable with those in wild-type mice in a model of ACD. Similarly, Il3-/- mice developed ACD pathology comparable with that of wild-type mice. Importantly, the blocking anti-human βc antibody CSL311 strongly suppressed ear pinna thickening and histopathological changes typical of ACD and reduced accumulation of neutrophils, mast cells, and eosinophils in the skin. These results show that GM-CSF and IL-5 but not IL-3 are major mediators of ACD and define the human βc receptor transgenic mouse as a unique platform to test the inhibitors of βc in vivo.
引用
- Yip KH, McKenzie D, Ramshaw HS, et al. Targeting the Human βc Receptor Inhibits Contact Dermatitis in a Transgenic Mouse Model. J Invest Dermatol. 2021. PMID: 34537191. doi:10.1016/j.jid.2021.07.183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。